Sector
1063 stories · page 50 of 54
Combining new technologies and healthcare expertise, the company’s key offerings include optimising clinical study design and recruitment strategies to better understand the patient experience.
The data concerns the TUSC2 tumor suppressor gene, which is an active agent in Genprex’s Oncoprex immunogene therapy
Study timelines are progressing as planned and at this point the trial should complete ahead of expectations.
Peak Processing is a Canadian cannabis co-packing and white label product manufacturing firm
Namaste currently holds a 49% interest in Choklat and revealed it had now struck a secured convertible loan deal
A few biotechs and a banking company went public Thursday morning, but not everyone made it to the finish line
The company’s chairman Peter Wall said the 2019 financial year was a significant year of transformation for MMJ in his letter to shareholders in the annual report.
ISS helps healthcare and pharma companies meeting with US regulators to discuss the next steps for their new drug or medical device
The clinical study was a blinded, randomised trial showing plasma concentrations were achieved quickly with a product half-life of about four hours.
“Having commenced a second shift at the beginning of the year in our current facility in San Antonio, the phased build out of this new facility will allow us to meet the growing requirements of our customers well into the future," said boss
Recent developments "provide not only more visibility for the company, but also validity for the technology and help expand shareholder base."
The viral load suppression rate after 10 weeks was 68%, 94% and 85% respectively for patients on a 350 mg, 525 mg, and 700 mg drug dose regimen
The water-soluble powder was shown to deliver target concentrations of THC, which provides consumers with confidence that they’re getting the correct dose
It is transferring ownership of its Israeli cell process development business, Atvio Biotech, and its South Korean cell development unit, CureCell
The Laval, Quebec-based company expects Phase 1 results to be released by December 2019 followed by Phase 2 in January 2020
AstraZeneca is competing with GSK to win the race to become the go-to maintenance treatment for people who have been treated for ovarian cancer
The venture will utilise ReNeuron's exosome-based drug delivery technology
Septima Maguire, who spent four years at Dechra Pharmaceuticals, will start her new role at Benchmark in November
Varner said “we have made significant progress in many areas of the company, including progress toward expansion of our clinical programs and sponsored research"
The patents cover its antibody and microchannel technology and the detection of cancer cells, which collectively is used to capture cells of interest in a biopsy